A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

A federal judge in Texas handed Novo Nordisk (NVO) a big win late Thursday in its battle against cheaper versions of its ...